Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. MSFT
6. NAVN
7. DFTX
8. CNC
9. KFY
10. SPY

Go back to Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180

October 29, 2015 10:46 AM EDT

UBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.

Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More

Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF Data

October 27, 2015 2:52 PM EDT

Roth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target after the company and Amgen (Nasdaq: AMGN)... More